Navicixizumab

Names

[ Name ]:
Navicixizumab

Biological Activity

[Description]:

Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel (HY-B0015) for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer[1][2][3].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> Stem Cell/Wnt >> Notch

[Target]

IC50: hVEGF (0.36 nM), mVEGF (25.5 nM), hDLL4 (1.3 nM)

[In Vitro]

Navicixizumab (0-100 μM) 在 hVEGF 存在的情况下减少人内皮细胞的增殖[3].

[In Vivo]

Navicixizumab (15 mg/kg，每周一次，持续 4 周) 抑制结肠异种移植肿瘤的生长[3]。

[References]

[1]. Fu S, et al. Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. J Clin Oncol. 2022 Aug 10;40(23):2568-2577.

[2]. Perez-Fidalgo JA, et al. NOTCH signalling in ovarian cancer angiogenesis. Ann Transl Med. 2020 Dec;8(24):1705.

[3]. Wan-Ching Yen, et al. Abstract C164: Dual targeting of the DLL4 and VEGF pathways with a bispecific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency. Mol Cancer Ther (2015) 14 (12_Supplement_2): C164.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.